title: Angioedema induced by angiotensin converting enzyme inhibitors, potentiated by m-TOR inhibitors: successful treatment with icatibant.
authors.affiliation: Service de Réanimation Polyvalente, Hôpital de Mercy, CHR Metz-Thionville, 1 Allée Du Château, 57530, Ars-Laquenexy, France, alexandre.charmillon@yahoo.fr.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Charmillon
authors.forename: Joëlle
authors.initials: J
authors.lastname: Deibener
authors.forename: Pierre
authors.initials: P
authors.lastname: Kaminsky
authors.forename: Guillaume
authors.initials: G
authors.lastname: Louis
mesh_terms: D000368:Aged; D000799:Angioedema / Q000139:chemically induced* / Q000188:drug therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D065094:Bradykinin B2 Receptor Antagonists / Q000627:therapeutic use*; D004357:Drug Synergism; D000068338:Everolimus; D005260:Female; D006801:Humans; D000077583:Quinapril; D012074:Remission Induction; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D044005:Tetrahydroisoquinolines / Q000009:adverse effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D065094:Bradykinin B2 Receptor Antagonists; D044005:Tetrahydroisoquinolines; C065679:icatibant; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D000077583:Quinapril; D001920:Bradykinin; D020123:Sirolimus